You are here

  • Home
  • Archive
  • Volume 11, Issue 8
  • Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis

 

Online download statistics by month:

Online download statistics by month: August 2023 to August 2025

AbstractFullPdf
Aug 2023451455117
Sep 2023427432101
Oct 202314415252
Nov 2023868621
Dec 2023636647
Jan 202420220465
Feb 202412312341
Mar 2024545565
Apr 2024636453
May 2024727336
Jun 2024575652
Jul 2024888950
Aug 2024464326
Sep 2024515145
Oct 2024515630
Nov 2024626356
Dec 2024676927
Jan 2025484938
Feb 202515515535
Mar 2025737345
Apr 202510110151
May 2025505037
Jun 2025333313
Jul 2025110
Aug 2025110
Total256926001103